SG11201807041PA - Improved preparations of adult liver progenitor cells - Google Patents

Improved preparations of adult liver progenitor cells

Info

Publication number
SG11201807041PA
SG11201807041PA SG11201807041PA SG11201807041PA SG11201807041PA SG 11201807041P A SG11201807041P A SG 11201807041PA SG 11201807041P A SG11201807041P A SG 11201807041PA SG 11201807041P A SG11201807041P A SG 11201807041PA SG 11201807041P A SG11201807041P A SG 11201807041PA
Authority
SG
Singapore
Prior art keywords
international
neuve
universite
place
preparations
Prior art date
Application number
SG11201807041PA
Inventor
Catherine Lombard
Pierre-Edouard Dollet
Etienne Sokal
Mustapha Najimi
Original Assignee
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Catholique Louvain filed Critical Univ Catholique Louvain
Publication of SG11201807041PA publication Critical patent/SG11201807041PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/14—Coculture with; Conditioned medium produced by hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 8 September 2017 (08.09.2017) WIPO I PCT (10) International Publication Number WO 2017/149059 Al 1111111111111101110111111111110101111101110101111111101111111111110111111111110111111 (51) International Patent Classification: C12N 5/071 (2010.01) G01N 33/50 (2006.01) A61K 35/407 (2015.01) (21) International Application Number: PCT/EP2017/054859 (22) International Filing Date: 2 March 2017 (02.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16158327.3 2 March 2016 (02.03.2016) EP (71) Applicant: UNIVERSITE CATHOLIQUE DE LOUV- AIN [BE/BE]; Place de l'Universite 1, 1348 Louv- ain-la-Neuve (BE). (72) Inventors: LOMBARD, Catherine; Place de l'Universite 1, 1348 Louvain-la-Neuve (BE). DOLLET, Pierre-Edou- ard; Place de l'Universite 1, 1348 Louvain-la-Neuve (BE). SOKAL, Etienne; Place de l'Universite 1, 1348 Louv - ain-la-Neuve (BE). NAJIMI, Mustapha; Place de versite 1, 1348 Louvain-la-Neuve (BE). (74) Agents: MICHALIK, Andrej et al.; E. Gevaertdreef 10a, 9830 Sint-Martens-Latem (BE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) W O 20 17 / 14905 9 Al (54) Title: IMPROVED PREPARATIONS OF ADULT LIVER PROGENITOR CELLS (57) : Preparations of adult liver progenitor cells (called HHALPCs) have been manufactured from different human donors and characterized by using cell surface markers that allow identifying HHALPCs preparations and/or the methods for producing them that are most suitable for cell therapy, in particular for treating liver diseases or inherited blood coagulation disorders.
SG11201807041PA 2016-03-02 2017-03-02 Improved preparations of adult liver progenitor cells SG11201807041PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16158327 2016-03-02
PCT/EP2017/054859 WO2017149059A1 (en) 2016-03-02 2017-03-02 Improved preparations of adult liver progenitor cells

Publications (1)

Publication Number Publication Date
SG11201807041PA true SG11201807041PA (en) 2018-09-27

Family

ID=55696855

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807041PA SG11201807041PA (en) 2016-03-02 2017-03-02 Improved preparations of adult liver progenitor cells

Country Status (14)

Country Link
US (1) US20190046584A1 (en)
EP (1) EP3423566A1 (en)
JP (1) JP2019506890A (en)
KR (1) KR20180114073A (en)
CN (1) CN108779440A (en)
AU (1) AU2017225825A1 (en)
BR (1) BR112018067597A8 (en)
CA (1) CA3013427A1 (en)
EA (1) EA039743B1 (en)
IL (1) IL261383A (en)
MA (1) MA45274A (en)
MX (1) MX2018010508A (en)
SG (1) SG11201807041PA (en)
WO (1) WO2017149059A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2759228T3 (en) 2013-07-05 2020-05-08 Univ Catholique Louvain Conditioned medium for adult liver stem cells and their use in the treatment of liver disorders
TW202035682A (en) 2018-12-14 2020-10-01 比利時商普羅米修亞生物科技股份有限公司 Liver progenitor cells expressing hla-g, and method for obtaining these cells compositions comprising said cells and their use
CA3122715A1 (en) 2018-12-14 2020-06-18 Promethera Therapeutics Sa Cell composition comprising liver progenitor cells expressing hla-e
US20220143100A1 (en) * 2019-03-26 2022-05-12 Promethera Therapeutics S.A. Adult Liver Progenitor Cells for Treating Acute-On-Chronic Liver Failure
EP3947645A1 (en) 2019-03-26 2022-02-09 Promethera Therapeutics Sa Adult liver progenitor cells for treating non-alcoholic fatty liver disease
CA3137785A1 (en) 2019-04-30 2020-11-05 Promethera Therapeutics Sa Preparation of human allogeneic liver-derived progenitor cells
TW202106874A (en) 2019-04-30 2021-02-16 比利時商普羅米修亞生物科技股份有限公司 Preparation of human allogeneic liver-derived progenitor cells
WO2021069553A1 (en) 2019-10-09 2021-04-15 Promethera Biosciences S.A./N.V. Use of liver progenitor or stem cells, lysates thereof, and/or conditioned medium in disorders characterized by vascular hyperpermeability
EP3881853A1 (en) 2020-03-20 2021-09-22 Promethera Therapeutics Sa Human allogeneic liver-derived progenitor cells for use in the treatment of inflammatory and infectious lung diseases and systemic inflammation
CN111778268B (en) * 2020-06-03 2022-06-21 武汉仝干医疗科技股份有限公司 Gene segment for enhancing detoxification function and modified HepG2 cell
WO2023180122A1 (en) 2022-03-24 2023-09-28 Université Catholique de Louvain Use of human allogenic liver-derived progenitor cells for treating and/or preventing cellular senescence

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
ES2359874T5 (en) * 2005-12-21 2014-12-12 Universite Catholique De Louvain Liver Stem Cells Isolated
CN103989710B (en) 2005-12-21 2019-11-15 鲁汶大学 Isolated liver stem cells
JP5822287B2 (en) * 2008-05-14 2015-11-24 公立大学法人横浜市立大学 Human hepatic stem cell, its preparation method, differentiation induction method and utilization method
US8415149B2 (en) * 2010-05-06 2013-04-09 Gwo Xi Stem Cell Applied Technology Co., Ltd. Hepatic progenitor cells and uses thereof
JP6034406B2 (en) * 2012-01-25 2016-11-30 ユニヴェルシテ カソリック ド ルーヴァンＵｎｉｖｅｒｓｉｔｅ Ｃａｔｈｏｌｉｑｕｅ Ｄｅ Ｌｏｕｖａｉｎ Compositions and methods for cell transplantation
ES2759228T3 (en) 2013-07-05 2020-05-08 Univ Catholique Louvain Conditioned medium for adult liver stem cells and their use in the treatment of liver disorders
SG11201601485UA (en) * 2013-08-28 2016-03-30 Promethera Biosciences S A N V Method for producing adult liver progenitor cells

Also Published As

Publication number Publication date
CN108779440A (en) 2018-11-09
WO2017149059A1 (en) 2017-09-08
EA201891913A1 (en) 2019-02-28
US20190046584A1 (en) 2019-02-14
EA039743B1 (en) 2022-03-05
MA45274A (en) 2019-01-09
AU2017225825A1 (en) 2018-08-16
CA3013427A1 (en) 2017-09-08
KR20180114073A (en) 2018-10-17
MX2018010508A (en) 2018-11-09
IL261383A (en) 2018-10-31
BR112018067597A8 (en) 2019-10-15
JP2019506890A (en) 2019-03-14
EP3423566A1 (en) 2019-01-09
BR112018067597A2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201806340YA (en) Zika virus vaccine
SG11201805993UA (en) Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201811432WA (en) Rna for cancer therapy
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201807195VA (en) Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201901961SA (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
SG11201805052YA (en) Therapeutic methods using erythrocytes
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same